AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Calliditas Therapeutics (NASDAQ:CALT)
-- USD
0.000 0.000%| Previous Close (in USD) | 40.0001 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 38.320/15.250 |
| EBITDA (in USD) | -386.35M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -3.09 |
| Total Assets (in USD) | 1900.549M |
|---|---|
| Total Liabilities (in USD) | 1565.743M |
| Revenue TTM (in USD) | 1206.888M |
| Cash (in USD) | 973.733M |
| Market Cap (in USD) | 1,018.426 M |
| Revenue Per Share TTM | 44.972 |
| Gross Profit TTM (in USD) | 787.678M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Calliditas Therapeutics
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Employees: 217
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Ms. Renee Aguiar-Lucander | Chief Exec. Officer | 1962 |
| 2. | Mr. Fredrik Johansson | Chief Financial Officer | 1977 |
| 3. | Dr. Katayoun Welin-Berger Ph.D. | VP of Operations | 1968 |
| 4. | Dr. Johan Haggblad Ph.D. | Chief Scientific Officer | 1958 |
| 5. | Mr. Mikael Widell | Head of Communications & IR | 1958 |
| 6. | Mr. Jonathan A. Schur | Group Gen. Counsel | 1953 |
| 7. | Ms. Sandra Frithiof | Head of HR | NA |
| 8. | Ms. Ann-Kristin Myde BSc | Head of Clinical Devel. & VP of Project Management | 1955 |
| 9. | Mr. Andrew B. Udell B.Sc., M.B.A. | Pres of North America Commercial | 1970 |
| 10. | Dr. Krassimir Mitchev | Head of Medical Affairs | 1959 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.040 0.091% | 44.69 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.400 0.909% | 44.4 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+5.535 1.244% | 446.685 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.840 0.464% | 613.35 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -409.417M | -513.373M | -436.151M | -32.501M | -132.049M |
| Minority Interest | 0M | 9.244M | 45.809M | 45.809M | 45.809M |
| Net Income | -412.268M | -509.537M | -436.511M | -32.578M | -132.049M |
| Selling General Administrative | 259.469M | 390.232M | 141.724M | 62.882M | 133.146M |
| Gross Profit | 787.678M | 229.347M | 0.874M | 184.829M | - |
| Reconciled Depreciation | 12.913M | 34.433M | 2.823M | 1.822M | 0.051M |
| Ebit | -434.855M | -524.456M | -379.72M | -28.019M | -133.191M |
| Ebitda | -421.942M | -524.455M | -378.851M | -25.13M | -133.14M |
| Depreciation And Amortization | 12.913M | 0.001M | 0.869M | 2.889M | 0.051M |
| Operating Income | -421.942M | -524.456M | -379.72M | -28.019M | -132.482M |
| Other Operating Expenses | 1224.821M | 753.802M | 383.095M | 212.708M | 133.197M |
| Interest Expense | 12.526M | 7.108M | 0.393M | 0.325M | 0.008M |
| Tax Provision | 2.851M | -3.836M | 0.36M | 0.077M | 0M |
| Interest Income | 50.195M | 0.102M | 0.547M | 0.926M | 0.006M |
| Net Interest Income | 12.526M | 11.083M | -56.431M | 0.601M | -0.002M |
| Income Tax Expense | 2.851M | -3.836M | 0.36M | 0.077M | 0.441M |
| Total Revenue | 802.879M | 229.347M | 0.874M | 184.829M | 0M |
| Total Operating Expenses | 1209.62M | 753.802M | 383.095M | 212.708M | 133.197M |
| Cost Of Revenue | 15.201M | - | - | - | - |
| Total Other Income Expense Net | 12.525M | 11.083M | -56.431M | -4.482M | 1.15M |
| Net Income From Continuing Ops | -412.268M | -509.537M | -436.511M | -32.578M | -132.049M |
| Net Income Applicable To Common Shares | -412.268M | -500.293M | -433.494M | -32.578M | -132.049M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 1900.549M | 1952.973M | 1459.91M | 1506.45M | 845.2M |
| Intangible Assets | 430.754M | 438.041M | 362.218M | 16.066M | 16.066M |
| Other Current Assets | 92.802M | 0.001M | 0.001M | 22.801M | 2.32M |
| Total Liab | 1565.743M | 1186.71M | 451.629M | 250.15M | 57.129M |
| Total Stockholder Equity | 334.806M | 766.263M | 1008.281M | 1210.491M | 788.071M |
| Other Current Liab | 287.876M | 28.381M | 13.922M | 51.792M | 25.626M |
| Common Stock | 2.383M | 2.383M | 2.094M | 1.998M | 1.548M |
| Capital Stock | 2.383M | 2.383M | 2.094M | 1.998M | 1.548M |
| Retained Earnings | -2305.573M | -1827.01M | -1453.554M | -918.596M | -488.096M |
| Good Will | 48.584M | 45.8M | 37.2M | 445.301M | - |
| Other Assets | 0M | -0.001M | 8.111M | 0.6M | 1.938M |
| Cash | 973.733M | 1249.094M | 955.507M | 996.304M | 753.54M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 407.144M | 325.231M | 135.446M | 105.619M | 53.37M |
| Current Deferred Revenue | 6.167M | 136.446M | 3.387M | - | 0.874M |
| Net Debt | 5.4M | -520.272M | -742.291M | -996.304M | -747.47M |
| Short Term Debt | 12.537M | - | 50.166M | - | 2.486M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 979.133M | 728.822M | 213.216M | - | 6.07M |
| Other Stockholder Equity | 2643.227M | 2581.583M | 2486.72M | 2133.179M | 1274.664M |
| Property Plant Equipment | - | 31.92M | 39.609M | 5.407M | 6.063M |
| Total Current Assets | 1275.152M | 1412.204M | 1012.772M | 1036.851M | 821.132M |
| Long Term Investments | - | 11.21M | 3.915M | 2.225M | 0.001M |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 188.189M | 159.462M | 56.375M | 17.746M | 46.586M |
| Long Term Debt | 939.508M | 713.03M | 189.164M | - | - |
| Inventory | 20.428M | 3.647M | 0.889M | - | 18.686M |
| Accounts Payable | 100.564M | 160.404M | 67.971M | 53.827M | 24.384M |
| Accumulated Other Comprehensive Income | -5.231M | 9.307M | -26.979M | -6.09M | -0.045M |
| Non Currrent Assets Other | -0M | 6.816M | 1.686M | - | 1.938M |
| Non Current Assets Total | 625.397M | 540.77M | 447.138M | 469.599M | 24.068M |
| Capital Lease Obligations | 27.088M | 15.792M | 24.052M | - | 6.07M |
| Long Term Debt Total | - | - | - | - | 3.584M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -5.144M | -24.34M | -172.607M | -18.072M | -1.888M |
| Total Cashflows From Investing Activities | -5.144M | -24.34M | -172.607M | -18.072M | -18.072M |
| Total Cash From Financing Activities | 575.99M | 435.162M | 768.558M | 198.835M | 716.572M |
| Net Income | -421.943M | -524.456M | -379.72M | -28.019M | -132.482M |
| Change In Cash | 293.587M | -40.797M | 242.764M | 97.365M | 588.823M |
| Begin Period Cash Flow | 955.507M | 996.304M | 753.54M | 656.175M | 57.352M |
| End Period Cash Flow | 1249.094M | 955.507M | 996.304M | 753.54M | 646.175M |
| Total Cash From Operating Activities | -311.354M | -461.588M | -309.181M | -71.011M | -128.191M |
| Depreciation | 12.913M | 34.433M | 2.823M | 1.822M | 0.051M |
| Other Cashflows From Investing Activities | -5.144M | -24.34M | -0.005M | -0.005M | -0.005M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -2.758M | -0.949M | - | - | - |
| Sale Purchase Of Stock | -0.236M | - | - | 213.151M | 741.476M |
| Other Cashflows From Financing Activities | 585.605M | 116.737M | -118.858M | -9.83M | -51.607M |
| Capital Expenditures | 2.512M | 22.654M | 0M | 16.184M | 0.118M |
| Change In Working Capital | 88.42M | 5.47M | 54.083M | -45.901M | 4.242M |
| Other Non Cash Items | -26.535M | 66.677M | -0.004M | 0.062M | -0.002M |
| Free Cash Flow | -313.866M | -484.242M | -309.181M | -87.195M | -128.191M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | DWS ESG Biotech LC | 2 years ago | 50551 |
| 2. | ActivePassive International Equity ETF | 2 years ago | 6893 |
| 3. | Fidelity Nasdaq Composite Index | 2 years ago | 5831 |
| 4. | Ironwood Inv Mgt Small Cap Core | 2 years ago | 1123 |
| 5. | Dimensional International Small Cap ETF | 2 years ago | 260 |
| 6. | Ironwood Micro Cap | 2 years ago | 247 |
| 7. | DFA VA International Small Portfolio | 2 years ago | 237 |
| 8. | Dimensional International Core Eq 2 ETF | 2 years ago | 8 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Bvf Inc | 2 years ago | 750000 |
| 2. | Deutsche Bank AG | 2 years ago | 50550 |
| 3. | Ironwood Investment Management LLC | 2 years ago | 25511 |
| 4. | Susquehanna International Group, LLP | 2 years ago | 9412 |
| 5. | Wells Fargo & Co | 2 years ago | 1500 |
| 6. | Advisor Group Holdings, Inc. | 2 years ago | 1172 |
| 7. | Optiver Holding B.V. | 2 years ago | 980 |
| 8. | UBS Group AG | 2 years ago | 952 |
| 9. | Planning Capital Management Corp | 2 years ago | 877 |
| 10. | SIMPLEX TRADING, LLC | 2 years ago | 671 |
| 11. | JPMorgan Chase & Co | 2 years ago | 607 |
| 12. | Morgan Stanley - Brokerage Accounts | 2 years ago | 602 |
| 13. | Bank of America Corp | 2 years ago | 313 |
| 14. | Rhumbline Advisers | 2 years ago | 164 |
| 15. | Colonial Asset Management Inc | 2 years ago | 105 |
| 16. | Cutler Group LP | 2 years ago | 100 |
| 17. | Qube Research & Technologies | 2 years ago | 72 |
| 18. | Tudor Investment Corp Et AL | 2 years ago | 65 |
| 19. | Missouri Trust & Investment Co | 2 years ago | 35 |
| 20. | Nalls Sherbakoff Group, LLC | 2 years ago | 18 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...